CURRENT OPPORTUNITIES FOR COMBINATION TREATMENT OF LOWER URINARY TRACT SYMPTOMS DUE TO BENIGN PROSTATIC HYPERPLASIA IN MEN

Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) are widely presented, particularly among elderly men. It was commonly accepted that LUTS are directly or indirectly connected with the prostate. Recent studies have shown that mild andsevere forms of LUTS may have a different etiology, such as, bladder related problems: overactive bladder (OAB)/detrusor overactivity or, conversely, an underactive bladder due to compromised contractions of the detrusor. There are three main groups of LUTS: storage symptoms, voiding symptoms and post-micturition symptoms. Patients with LUTS/BPH who are not sufficiently respond to monotherapy with alpha-blockers should receive additional treatment with M‑anticholinergics in accordance with the European urological guidelines. Current studies show that up to 65% of patients with LUTS/BPH with symptoms of urgency and frequency do not have sufficient reduction of symptoms after 3 months of treatment with alphablocker as monotherapy. Until recently, alpha-blockers and M‑anticholinergic medications were prescribed in combination therapy as a two separate pills. Vesomni is a combination of antimuscarinic drug solifenacin 6 mg with α1‑blocker tamsulosin OCAS 0.4 mg in one tablet. It is developed to relieve storage (urgency and frequency) and voiding symptoms in men with LUTS/BPH. Solifenacin suppresses the overactivity of the detrusor and reduces storage symptoms. Tamsulosin OCAS relaxes smooth muscle of the prostate, prostatic urethra and bladder neck, and eliminates most voiding symptoms and, to a lesser extent, storage symptoms.

1. Abrams P., Cardozo L., Fall M., Griffiths D., Rosier P., Ulmsten U., et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003; 61 (1): 37–49.

2. Chung D. E., Sandhu J. S. Overactive bladder and outlet obstruction in men. Curr Urol Rep. 2011; 12 (1): 77–85. doi: 10.1007/s11934–010–0157 x.

3. Speakman M.J. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): more than treating symptoms? Eur Urol Suppl. 2008; 7: 680–689.

4. Irwin D. E., Milsom I., Hunskaar S., Reilly K., Kopp Z., Herschorn S., et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006; 50 (6): 1306–1314.

5. Sexton C. C., Coyne K. S., Kopp Z. S., Irwin D. E., Milsom I., Aiyer L. P., et al. The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS. BJU Int 2009; 103 (Suppl 3): 12–23. doi: 10.1111/j.1464–410X.2009.08369.x.

6. Irwin D. E., Kopp Z. S., Agatep B., Milsom I., Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int 2011; 108: 1132–1138. doi: 10.1111/j.1464–410X.2010.09993.x. Epub 2011 Jan 13.

7. Kupelian V., Wei J. T., O’Leary M. P., Kusek J.W., Litman H.J., Link C. L., et al. Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey. Arch Intern Med. 2006; 166 (21): 2381–2387.

8. Coyne K. S., Wein A.J., Tubaro A., Sexton C. C., Thompson C. L., Kopp Z. S., et al. The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS. BJU Int 2009; 103 (Suppl 3): 4–11. doi: 10.1111/j.1464–410X.2009.08371.x.

9. Emberton M., Marberger M., de la Rosette J. Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: the Prostate Research on Behaviour and Education (PROBE) Survey. Int J Clin Pract. 2008; 62 (1): 18–26.

10. Sells H., Donovan J., Ewings P., MacDonagh R.P. The development and validation of a quality-of-life measure to assess partner morbidity in benign prostatic enlargement. BJU Int 2000; 85 (4): 440–445.

11. Peters T.J., Donovan J. L., Kay H. E., Abrams P., de la Rosette J.J., Porru D., et al. The International Continence Society “Benign Prostatic Hyperplasia” study: the bothersomeness of urinary symptoms. J Urol. 1997; 157 (3): 885–889.

12. Häkkinen J. T., Hakama M., Huhtala H., Shiri R., Auvinen A., Tammela T. L., et al. Impact of LUTS using bother index in DANPSS 1 questionnaire. Eur Urol. 2007; 51 (2): 473–477.

13. Asplund R. Nocturia: consequences for sleep and daytime activities and associated risks. Eur Urol. 2005; 3 (Suppl): 24–32.

14. Gravas S., Bach T., Bachmann A., Drake M., Gacci M., Gratzke C., et al. EAU guidelines on the management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO) 2016. Available at: http://uroweb. org/wp-content/uploads/EAU-Guidelines-Management-ofnon-neurogenic-male-LUTS 2016.pdf (Accessed: 01.02.2016).

15. McVary K. T., Roehrborn C.G., Avins A. L., Barry MJ., Bruskewitz R. C., Donnell R.F, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 2011;185 (5): 1793–1803. doi: 10.1016/j.juro.2011.01.074. Epub 2011 Mar 21.

16. Roehrborn C.G. Clinical management of lower urinary tract symptoms with combined medical therapy. BJU Int. 2008; 102 Suppl 2: 13–17. doi: 10.1111/j.1464–410X.2008.08088.x.

17. van Kerrebroeck P., Jardin A., Laval K.U., van Cangh P. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. Eur Urol. 2000; 37: 306–313.

18. Chapple C. R., Al-Shukri S.H., Gattegno B., et al. Tamsulosin Oral Controlled Absorption System (OCAS) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): efficacy and tolerability in a placebo and active comparator controlled phase 3a study. Eur Urol. 2005; 4 Suppl: 33–44.

19. Narayan P., Evans C. P., Moon T. Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol. 2003; 170: 498–502.

20. Chapple C. R., Roehrborn C.G. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol. 2006; 49: 651–658.

21. Lee J. Y., Kim H.W., Lee S.J., Koh J. S., Suh H.J., Chancellor M. B., et al. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int. 2004; 94 (6): 817–820.

22. McVary K. T. BPH: epidemiology and comorbidities. Am J Manag Care. 2006; 12: S122–128.

23. Krivoborodov G.G. Lower urinary tract symptoms in men. Urologiia. 2014; 1: 49–54.

24. Gadzhieva Z. K., Kazilov Yu. B., Alyaev Yu.G., Aboyan I. A., Kazilov B. R. Urination disorders. Do we know all about them? Urologiia. 2014; 1: 20–26. (Russian).

25. Pushkar D.Yu., Rasner P. I. Experience in administration of cholinolytics in the treatment of patients with prostatic adenoma and symptoms of the lower urinary tract. Urologiia. 2011; 2: 80–85. Russian).

26. Veliyev E. I., Golubtsova E.N., Dadashev E.O. Necessity and safety of combined drug therapy in patients with urination disorders. Urologiia. 2012; 4: 92–96. (Russian).

27. MacDiarmid S. A., Peters K. M., Chen A., Armstrong R. B., Orman C., Aquilina J. W., et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebocontrolled study. Mayo Clin Proc 2008; 83 (9): 1002–1058. doi: 10.4065/83.9.1002.

28. Chapple C., Herschorn S., Abrams P., Sun F., Brodsky M., Guan Z.. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol. 2009; 56 (3): 534–541. doi: 10.1016/j. eururo.2008.11.026. Epub 2008 Nov 24.

29. Kaplan SA, McCammon K, Fincher R, Fakhoury A, He W. Safety and tolerability of solifenacin add-on therapy to -blocker treated men with residual urgency and frequency. J Urol. 2009; 182 (6): 2825–2830. doi: 10.1016/j.juro.2009.08.023. Epub 2009 Oct 17.

30. Yamaguchi O., Kakizaki H., Homma Y., Takeda M., Nishizawa O., Gotoh M., et al. Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms-ASSIST, randomized controlled study. Urology. 2011; 78 (1): 126–133. doi: 10.1016/j.urology.2011.02.055. Epub 2011 May 23.

31. Berry S.J., Coffey D. S., Walsh P. C., Ewing L. L.. The development of human benign prostratic hyperplasia with age. J Urology. 1984; 132 (3): 474–479.

32. Van Kerrebroeck P., Chapple C., Drogendijk T., Klaver M., Sokol R., Speakman M., et al; NEPTUNE Study Group. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. Eur Urol. 2013; 64 (16): 1003–1012. doi: 10.1016/j.eururo.2013.07.034. Epub 2013 Aug 3.

33. Drake M.J., Chapple C., Sokol R., Oelke M., Traudtner K., Klaver M., et al. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension. Eur Urol. 2015; 67 (2): 262–270. doi: 10.1016/j.eururo.2014.07.013. Epub 2014 Jul 25.

34. Nazir J., Heemstra L., van Engen A., Hakimi Z., Ivanescu C. Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia. BMC Urol. 2015 May 9;15:41. doi: 10.1186/s12894–015–0031–8.